Full Press Release Details
to Present at H.C. Wainwright 27th Annual Global Investment Conference
LAKE CITY, UT, September 5, 2025/PR NEWSWIRE/ - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary
technology platform to develop innovative products with effective oral delivery, today announced that Company Management will present
and meet with investors at the H.C. Wainwright 27th Annual Global Investment Conference being held in-person and virtually
on September 8-10, 2025.
| Time: | Available from 7:00 a.m. EDT onwards |
| Date: | Friday, September 5, 2025 |
can register for the conference here. Those interested in arranging a 1x1 meeting with Lipocine should contact their H.C. Wainwright
is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery.
Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent
enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable
markets with significant unmet medical needs.
clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101
for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral
proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in
obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms
associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm
birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated
cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral
prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with
a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
further information: